The US Food and Drug Administration (FDA) found the Questionnaire for Visual Disturbances (QUVID) is a “fit-for-purpose measure” to capture ocular symptoms both prior to and following the implantation of intraocular lenses (IOLs), according to a study published in the American Journal of Ophthalmology.
The development of QUVID was based on a literature and instrument review consisting of 13 interviews with ophthalmologists and 67 interviews with adult patients before or after monofocal, traditional multifocal, or trifocal IOL implantation.
QUVID’s psychometric properties were evaluated via a non interventional, cross-sectional, standalone study of previously treated patients with cataracts (n=150). An assessment of ability to detect meaningful change was performed in patients with trifocal or extended vision IOL compared with a monofocal IOL control group (n=457).
The QUVID included questions regarding the frequency, severity, and bothersomeness of 7 visual symptoms: starbursts, halos, glare, hazy vision, blurred vision, double vision, and dark area.
Bothersomeness was considered to be the item of most clinical relevance and variability in patients who were symptomatic, the researchers note. The QUVID could potentially identify a meaningful decrease in pre and postoperative bothersomeness utilizing both ordinal and interval measurement scaling assumptions.
Limitations of the research include the psychometric study’s sample size and the large confidence bounds for measures of test-retest reliability.
Disclosure: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. This research was supported by Alcon Laboratories. Please see the original reference for a full list of disclosures.
Lasch K, Marcus JC, Seo C, et al. Development and validation of a visual symptom-specific patient-reported outcomes instrument for adults with cataract IOL implants. Am J Ophthalmol. Published online November 2, 2021. doi:10.1016/j.ajo.2021.10.023